These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 33086996)

  • 1. Short-term effectiveness of ixekizumab to refractory psoriatic arthritis with spondyloarthritis: two case reports.
    Nagayasu A; Nawata M; Saito K; Tanaka Y
    Mod Rheumatol Case Rep; 2020 Jul; 4(2):176-180. PubMed ID: 33086996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment-emergent Candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with ixekizumab: an integrated safety analysis of 25 clinical studies.
    Schwartzman S; Puig L; Cohen AD; Khattri S; Jossart C; Diaz C; Garrelts A; Ngantcha M; Eberhart N; Eleftheriadi A; Tangsirisap N; Schuster C; Gottlieb AB
    Expert Opin Drug Saf; 2024 Oct; 23(10):1347-1357. PubMed ID: 39234767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis.
    Toussirot E
    Expert Opin Biol Ther; 2018 Jan; 18(1):101-107. PubMed ID: 29187009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2.
    Deodhar A; Gladman D; Bolce R; Sandoval D; Park SY; Leage SL; Nash P; Poddubnyy D
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X231189005. PubMed ID: 37645684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).
    Dougados M; Wei JC; Landewé R; Sieper J; Baraliakos X; Van den Bosch F; Maksymowych WP; Ermann J; Walsh JA; Tomita T; Deodhar A; van der Heijde D; Li X; Zhao F; Bertram CC; Gallo G; Carlier H; Gensler LS;
    Ann Rheum Dis; 2020 Feb; 79(2):176-185. PubMed ID: 31685553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).
    van der Heijde D; Gladman DD; Kishimoto M; Okada M; Rathmann SS; Moriarty SR; Shuler CL; Carlier H; Benichou O; Mease PJ
    J Rheumatol; 2018 Mar; 45(3):367-377. PubMed ID: 29247148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study.
    Kristensen LE; Ng KJ; Ngantcha M; Morel J; Lubrano E; Tillett W; Alten R; Chandran V; Martinez Ferrer À; Zhu B; Kennedy D; Holzkämper T; Gullick N; Kronbergs A; Fakhouri W; de la Torre I; McGonagle DG
    RMD Open; 2024 Sep; 10(3):. PubMed ID: 39306343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ixekizumab therapy following secukinumab inadequate response in psoriatic arthritis: a case series focusing on axial disease.
    Panagiotopoulos A; Koutsianas C; Kougkas N; Moschou D; Bournia VK; Gazi S; Tektonidou MG; Vassilopoulos D; Sfikakis PP; Fragoulis GE
    Rheumatol Int; 2023 May; 43(5):969-973. PubMed ID: 36840819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies.
    McGonagle DG; McInnes IB; Kirkham BW; Sherlock J; Moots R
    Ann Rheum Dis; 2019 Sep; 78(9):1167-1178. PubMed ID: 31278139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.
    Deodhar A; Blauvelt A; Lebwohl M; Feely M; Kronbergs A; Eberhart N; Zhu D; Inman E; Grace E; Holzkaemper T; Rahman P; Marzo-Ortega H; Papp KA; Merola JF; Gottlieb AB; Schwartzman S
    Arthritis Res Ther; 2024 Feb; 26(1):49. PubMed ID: 38347650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
    Vu TT; Gooderham M; Papp K
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
    Mease PJ; van der Heijde D; Ritchlin CT; Okada M; Cuchacovich RS; Shuler CL; Lin CY; Braun DK; Lee CH; Gladman DD;
    Ann Rheum Dis; 2017 Jan; 76(1):79-87. PubMed ID: 27553214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
    Mease PJ; Smolen JS; Behrens F; Nash P; Liu Leage S; Li L; Tahir H; Gooderham M; Krishnan E; Liu-Seifert H; Emery P; Pillai SG; Helliwell PS;
    Ann Rheum Dis; 2020 Jan; 79(1):123-131. PubMed ID: 31563894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of ixekizumab in the treatment of psoriatic arthritis.
    O'Rielly DD; Rahman P
    Expert Rev Clin Immunol; 2018 Dec; 14(12):993-1002. PubMed ID: 30360663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ixekizumab in the treatment of psoriatic arthritis.
    Lespessailles E; Toumi H
    Immunotherapy; 2021 Jan; 13(1):19-33. PubMed ID: 33167745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors.
    Kirkham B; Sesin C; Gellett AM; Sprabery AT; Lin CY; Turkiewicz A
    Rheumatology (Oxford); 2021 Sep; 60(9):4367-4372. PubMed ID: 33479721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1).
    Chandran V; van der Heijde D; Fleischmann RM; Lespessailles E; Helliwell PS; Kameda H; Burgos-Vargas R; Erickson JS; Rathmann SS; Sprabery AT; Birt JA; Shuler CL; Gallo G
    Rheumatology (Oxford); 2020 Oct; 59(10):2774-2784. PubMed ID: 32031665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ixekizumab for the treatment of psoriasis: an update on new data since first approval.
    Blegvad C; Skov L; Zachariae C
    Expert Rev Clin Immunol; 2019 Feb; 15(2):111-121. PubMed ID: 30589394
    [No Abstract]   [Full Text] [Related]  

  • 19. Ixekizumab for treating ankylosing spondylitis.
    Kiwalkar S; Beier S; Deodhar A
    Immunotherapy; 2019 Oct; 11(15):1273-1282. PubMed ID: 31530049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psoriatic arthritis and spondyloarthritis assessment and management update.
    Mease P
    Curr Opin Rheumatol; 2013 May; 25(3):287-96. PubMed ID: 23492739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.